<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795674</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2020-0305</org_study_id>
    <nct_id>NCT04795674</nct_id>
  </id_info>
  <brief_title>Target ADHD Executive Working Memory Study</brief_title>
  <official_title>Behavioral and Neural Target Engagement for ADHD Executive Working Memory Training</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether or not a novel executive working memory training intervention&#xD;
      for Attention-Deficit/Hyperactivity Disorder can engage frontoparietal brain network&#xD;
      treatment targets and behavioral performance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposal seeks support for a 2-year milestone-driven R61 initial test of target&#xD;
      engagement in n=62 ADHD diagnosed adolescents randomized to a 'sham training' placebo or to&#xD;
      train 4 times each week using 4 different EWM exercises that have been combined into the&#xD;
      format of a typical cognitive training intervention. Exercise difficulty levels in the active&#xD;
      intervention will increase across 5 weeks to continually challenge EWM ability. EWM training&#xD;
      will use a novel, remotely-supervised 'at home' computerized training approach. If R61 EWM&#xD;
      training target engagement milestones are met, a 3-year R33 phase will begin. The R33 will&#xD;
      replicate target engagement in another randomized placebo-controlled trial of n=90 new ADHD&#xD;
      adolescents and attempt to establish a convincing link between the hypothesized targets and&#xD;
      ADHD symptom expression. It also will characterize ADHD brain activity or EWM ability changes&#xD;
      relative to typical levels seen in an n=40 non-ADHD control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetic Resonance Imaging Functional Brain Scan using a Seimens 3T Skyra.</measure>
    <time_frame>Change in fMRI measurements from baseline assessment versus 5 weeks at the conclusion of training</time_frame>
    <description>fMRI measures of brain activation and functional connectivity - Conventional measures of 'brain activation' are estimated using GLM regression models that fit the fMRI BOLD timeseries data to a model of expected hemodynamic change as elicited by fMRI versions of the executive working memory training task trials. Functional connectivity is assessed using a form of cross-correlation analysis that quantifies how much the entire BOLD timeseries in different brain regions are similar to one another. Our a priori treatment target brain regions are the superior frontal sulcus and mid-lateral prefrontal cortex region of interest. Brain activity and functional connectivity specifically to these regions represent the primary outcome measures of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The experimental executive working memory training tasks</measure>
    <time_frame>Change in scores from baseline assessment versus 5 weeks at the conclusion of training</time_frame>
    <description>Will examine changes in performance accuracy on the 4 executive working memory training tasks. These are experimental, non-published tasks being tested in this project for the first time.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>ADHD EWM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive EWM training sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADHD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo training sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>EWM Training</intervention_name>
    <description>Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.</description>
    <arm_group_label>ADHD EWM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Placebo Training</intervention_name>
    <description>Hoyle's tile games</description>
    <arm_group_label>ADHD Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ADHD&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  &gt;5th grade reading level&#xD;
&#xD;
          -  &gt;80 IQ level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Braces, metal or implant devices&#xD;
&#xD;
          -  Brain abnormality, neurological disorder&#xD;
&#xD;
          -  TBI or loss of consciousness&gt;30 minutes&#xD;
&#xD;
          -  Diagnosis of Psychosis, Bipolar Disorder, ASD, PTSD, OCD, SUD, Tourette's Disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Living/Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Karen L Kesten, MS</last_name>
      <phone>860-545-7776</phone>
      <email>Karen.kesten@hhchealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Jacey Anderson, BS</last_name>
      <phone>(860) 545-7531</phone>
      <email>Jacey.anderson@hhchealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael C Stevens, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>Michael Stevens</investigator_full_name>
    <investigator_title>Senior Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Adolescents</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT04795674/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

